Nymox Pharmaceutical Corporation (NYMX) Company Bio
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer. This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment. The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection Treatment of Grade Group 1 Prostate Cancer: Four Year Results”.
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.